Cargando…

MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)

BACKGROUND: The development of biomarkers for the early detection of non‐small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jipei, Shen, Jun, Leng, Qixin, Qin, Meng, Zhan, Min, Jiang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049510/
https://www.ncbi.nlm.nih.gov/pubmed/31994346
http://dx.doi.org/10.1111/1759-7714.13337
_version_ 1783502456094720000
author Liao, Jipei
Shen, Jun
Leng, Qixin
Qin, Meng
Zhan, Min
Jiang, Feng
author_facet Liao, Jipei
Shen, Jun
Leng, Qixin
Qin, Meng
Zhan, Min
Jiang, Feng
author_sort Liao, Jipei
collection PubMed
description BACKGROUND: The development of biomarkers for the early detection of non‐small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types of specimens could improve the early detection of NSCLC. METHODS: Using reverse transcription PCR, we determined expressions of two miRNAs (miRs‐31‐5p and 210‐3p) in sputum and three miRNAs (miRs‐21‐5p, 210‐3p, and 486‐5p) in plasma of a training cohort of 76 NSCLC patients and 72 cancer‐free smokers. The results were validated in a testing cohort of 56 NSCLC patients and 55 cancer‐free smokers. RESULTS: The panels of two sputum miRNAs and three plasma miRNAs had 65.8–75.0% sensitivities and 83.3–87.5% specificities for diagnosis of NSCLC in the training cohort. The individual sputum or plasma miRNA panel had a higher sensitivity for squamous cell carcinoma or adenocarcinoma of the lung, respectively. From the miRNAs, we optimized an integrated panel of biomarkers consisting of two sputum miRNAs (miRs‐31‐5p and 210‐3p) and one plasma miRNA (miR‐21‐5p) that had higher sensitivity (85.5%) and specificity (91.7%) for diagnosis of NSCLC compared with the individual panels alone. Furthermore, the performance of the integrated panel of biomarkers was independent of histology and stage of NSCLC, and patients' age, sex, and ethnicity. The performance of the integrated panel of biomarkers was confirmed in the testing cohort. CONCLUSIONS: Integrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC. KEY POINTS: Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone.
format Online
Article
Text
id pubmed-7049510
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-70495102020-03-05 MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC) Liao, Jipei Shen, Jun Leng, Qixin Qin, Meng Zhan, Min Jiang, Feng Thorac Cancer Original Articles BACKGROUND: The development of biomarkers for the early detection of non‐small cell lung cancer (NSCLC) is clinically important. We have developed miRNA biomarkers in sputum and plasma, respectively, for NSCLC. Herein, we evaluate whether integrated analysis of the miRNAs across the different types of specimens could improve the early detection of NSCLC. METHODS: Using reverse transcription PCR, we determined expressions of two miRNAs (miRs‐31‐5p and 210‐3p) in sputum and three miRNAs (miRs‐21‐5p, 210‐3p, and 486‐5p) in plasma of a training cohort of 76 NSCLC patients and 72 cancer‐free smokers. The results were validated in a testing cohort of 56 NSCLC patients and 55 cancer‐free smokers. RESULTS: The panels of two sputum miRNAs and three plasma miRNAs had 65.8–75.0% sensitivities and 83.3–87.5% specificities for diagnosis of NSCLC in the training cohort. The individual sputum or plasma miRNA panel had a higher sensitivity for squamous cell carcinoma or adenocarcinoma of the lung, respectively. From the miRNAs, we optimized an integrated panel of biomarkers consisting of two sputum miRNAs (miRs‐31‐5p and 210‐3p) and one plasma miRNA (miR‐21‐5p) that had higher sensitivity (85.5%) and specificity (91.7%) for diagnosis of NSCLC compared with the individual panels alone. Furthermore, the performance of the integrated panel of biomarkers was independent of histology and stage of NSCLC, and patients' age, sex, and ethnicity. The performance of the integrated panel of biomarkers was confirmed in the testing cohort. CONCLUSIONS: Integrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC. KEY POINTS: Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone. John Wiley & Sons Australia, Ltd 2020-01-28 2020-03 /pmc/articles/PMC7049510/ /pubmed/31994346 http://dx.doi.org/10.1111/1759-7714.13337 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Liao, Jipei
Shen, Jun
Leng, Qixin
Qin, Meng
Zhan, Min
Jiang, Feng
MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
title MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
title_full MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
title_fullStr MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
title_full_unstemmed MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
title_short MicroRNA‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
title_sort microrna‐based biomarkers for diagnosis of non‐small cell lung cancer (nsclc)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049510/
https://www.ncbi.nlm.nih.gov/pubmed/31994346
http://dx.doi.org/10.1111/1759-7714.13337
work_keys_str_mv AT liaojipei micrornabasedbiomarkersfordiagnosisofnonsmallcelllungcancernsclc
AT shenjun micrornabasedbiomarkersfordiagnosisofnonsmallcelllungcancernsclc
AT lengqixin micrornabasedbiomarkersfordiagnosisofnonsmallcelllungcancernsclc
AT qinmeng micrornabasedbiomarkersfordiagnosisofnonsmallcelllungcancernsclc
AT zhanmin micrornabasedbiomarkersfordiagnosisofnonsmallcelllungcancernsclc
AT jiangfeng micrornabasedbiomarkersfordiagnosisofnonsmallcelllungcancernsclc